US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bayer A.G.

6.80

-0.0500-0.73%

Volume:274.48K

Turnover:1.87M

Market Cap:26.72B

PE:-10.10

High:6.84

Open:6.78

Low:6.78

Close:6.85

Loading ...

Overview Company News Filings

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat

PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose

Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk

PCRX Stock Soars on Exparel Patent Settlement With Generic Players

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

Bayer Asks Supreme Court to Review Roundup Case

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication

FMC, Bayer collaborate to bring Isoflex to European markets

Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BAYRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":6.8,"timestamp":1746561600000,"preClose":6.85,"halted":0,"volume":274482,"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.672948,"marketStatus":"Closed","change":-0.05,"latestTime":"05-06 16:00:00 EDT Delay","open":6.78,"high":6.84,"low":6.78,"amount":1865887.5114000004,"amplitude":0.008759,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.672948,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746604800000},"marketStatusCode":5,"adr":0,"adrRate":0.25,"exchange":"PINK","adjPreClose":6.85,"volumeRatio":0.702859},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"3.00%","roe":"-7.82%","lyrEps":-0.672948,"volumeRatio":0.702859,"shares":3929696328,"dividePrice":0.031179,"high":6.84,"amplitude":0.008759,"preClose":6.85,"low":6.78,"week52Low":4.79,"pbRate":"0.74","psRate":"0.51","week52High":8.58,"institutionHeld":0,"latestPrice":6.8,"eps":-0.672948,"divideRate":0.004585,"volume":274482,"delay":15,"ttmEps":-0.672948,"open":6.78,"prevYearClose":4.88,"prevWeekClose":6.74,"prevMonthClose":6.59,"prevQuarterClose":6.02,"fiveDayClose":6.6,"twentyDayClose":5.45,"sixtyDayClose":5.42,"earningDate":1747065600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527247077","title":"DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2527247077","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527247077?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:52","pubTimestamp":1744807920,"startTime":"0","endTime":"0","summary":"Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast Track designation to PBGENE-HBV. This is DTIL’s lead, fully owned in vivo gene editing program aimed at curing chronic hepatitis B by eliminating cccDNA — the primary source of replicating hepatitis B virus  — and inactivating integrated HBV DNA in liver cells .The FDA’s Fast Track designation is intended to speed up the development and review of drugs that treat serious conditions and fulfill unmet medical needs. It offers benefits, such as more frequent FDA interactions, rolling submission of marketing applications, and potential eligibility for Priority Review if certain conditions are met.According to Precision BioSciences, PBGENE-HBV is the first and only gene editing program with this unique mechanism of action to enter the clinical stage as a potential cure.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dtil-gets-fdas-fast-track-125200444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DTIL","IE00B5TLWC47.USD","BK4585","BK4007","BK4139","FAST","IE00BYQQ9H92.USD","DVAX","IE00BFXG0V08.USD","BK4104","BK4567","BAYRY","BK4588","ADMA"],"gpt_icon":0},{"id":"2527290404","title":"VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527290404","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527290404?lang=en_us&edition=fundamental","pubTime":"2025-04-16 00:27","pubTimestamp":1744734420,"startTime":"0","endTime":"0","summary":"Shares of Verve Therapeutics VERV surged 26.4% on Monday and continue to soar today after the company announced positive initial datafrom an early-stage study of its investigational candidate, VERVE-102, which is being developed for reducing cholesterol levels. VERVE-102 is a novel,in vivo, investigational base editing medicine.The data readout includes 14 patients from the first three cohorts who received doses of VERVE-102 at 0.3 mg/kg, 0.45 mg/kg, or 0.6 mg/kg, respectively, with each participant having at least 28 days of follow-up as of the data cutoff date of March 13, 2025.More on VERV’s Phase I Cholesterol Drug Study Data. Verve Therapeutics reported that a single infusion of VERVE-102 resulted in dose-dependent reductions in blood PCSK9 protein levels and LDL-C in the Heart-2 study, with an average LDL-C decrease of 53% and a maximum reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verv-stock-soars-superior-efficacy-162700742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443549.SGD","LU0943347566.SGD","LU2491050071.SGD","LU0122379950.USD","LU2063271972.USD","LU0640476718.USD","LU2360106947.USD","IE00BK4W5M84.HKD","BK4585","LU0198837287.USD","LU1127390331.HKD","LU1720051108.HKD","LU0820561909.HKD","LU1623119135.USD","LU0079474960.USD","LU2491050154.USD","LU2471134796.USD","LU1035775433.USD","LU2023250504.SGD","LU1551013425.SGD","SG9999015978.USD","LU0672654240.SGD","LU1023059063.AUD","BK4588","ADMA","LU1093756168.USD","LU2468319806.SGD","GB00BDT5M118.USD","SG9999001176.SGD","LU2089984988.USD","LU0094547139.USD","LU0238689110.USD","LU0058720904.USD","LU1280957306.USD","IE00BK4W5L77.USD","LU2357305700.SGD","LU2324357040.USD","LU0106261372.USD","LU1720051017.SGD","SGXZ81514606.USD","VERV","LU0320765059.SGD","LU1712237335.SGD","LU2471134879.HKD","IE0009355771.USD","LU1093756325.SGD","LLY","BAYRY","SG9999015986.USD","LU1868836757.USD"],"gpt_icon":1},{"id":"2527524165","title":"Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2527524165","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527524165?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:00","pubTimestamp":1744635600,"startTime":"0","endTime":"0","summary":"Pharmaceutical and agriculture conglomerate Bayer said it could stop producing the world's most popular weedkiller, unless it gets court protection against lawsuits blaming the herbicide for causing cancer.Roundup has generated tens of billions of dollars in sales over time for Bayer and Monsanto, the biotech seed giant and developer of Roundup that Bayer acquired in 2018. Bayer currently produces about 40% of the world's glyphosate, which farmers spray across fields to tame crop-threatening weeds.But over the past decade, the herbicide has also brought Bayer a wave of litigation, pressuring its share price and costing about $10 billion in payouts to plaintiffs. In early March, Bayer told farmers, suppliers and retailers that it may stop selling Roundup, which would leave U.S. farmers reliant on imported glyphosate from China.\"We're pretty much reaching the end of the road,\" Bayer Chief Executive Bill Anderson said in an interview. \"We're talking months, not years.\". Since taking over ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2526761082","title":"NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2526761082","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526761082?lang=en_us&edition=fundamental","pubTime":"2025-04-12 01:17","pubTimestamp":1744391820,"startTime":"0","endTime":"0","summary":"Swiss pharma giant Novartis NVS announced a planned $23 billion investment over five years in U.S.-based infrastructure.Backed by this investment, the company intends to manufacture all key drugs for its U.S. patients in the country.NVS' decision to expand its current manufacturing, research and technology presence across the country follows President Trump's announcement of tariffs on pharmaceutical imports.The company's shares are up in pre-market. Novartis’ shares have risen 8.7% year to date against the industry’s decline of 8.2%.NVS expanded its manufacturing and R&D presence in the country by investing in 10 facilities, including seven brand-new ones.Over the next five years, Novartis will establish a biomedical research innovation hub in San Diego, CA, its second global R&D hub in the United States. This is expected to open during 2028-2029.These investments will ensure Novartis has manufacturing capacity in the United States for all its core technology platforms, including smal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvs-plans-invest-23b-us-171700008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","LU0070302665.USD","BK4588","IE0002141913.USD","BAYRY","BK4532","LU0320765489.SGD","IE0009355771.USD","NVS","BK4578","IE00B2B36J28.USD","BK4139","BK4585","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4007","LU0208291251.USD","ADMA","IE00BJT1NW94.SGD","LU0211331839.USD"],"gpt_icon":0},{"id":"2526511532","title":"PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2526511532","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526511532?lang=en_us&edition=fundamental","pubTime":"2025-04-10 22:53","pubTimestamp":1744296780,"startTime":"0","endTime":"0","summary":"Shares of Phio Pharmaceuticals PHIO rallied 52.5% on Wednesday after the company announced that the Safety Monitoring Committee  has recommended dose escalation in an early-stage study of the company’s investigational skin cancer candidate, PH-762.PH-762 is Phio Pharmaceuticals’ lead and only clinical-stage candidate, which is being developed leveraging its proprietary IntasylsiRNA gene silencing technology to eliminate cancer. The phase Ib dose escalation study is evaluating the safety and tolerability of neoadjuvant use of intratumoral PH-762 for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.The SMC’s decision allowing escalation to the next dose concentration was based on the favorable safety profile of the drug observed in the third cohort of the phase Ib study, which enrolled three patients with cutaneous squamous cell carcinoma. In these patients, injections were well tolerated, with no serious adverse events or dose-limiting toxicities. Pathology results a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-stock-soars-safety-panel-145300505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ADMA","BAYRY","BK4144","DVAX","PHIO","SMC","BK4139"],"gpt_icon":0},{"id":"2526899425","title":"Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526899425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526899425?lang=en_us&edition=fundamental","pubTime":"2025-04-10 15:36","pubTimestamp":1744270560,"startTime":"0","endTime":"0","summary":"0736 GMT - European pharma stocks jump at Thursday's market open, mirroring broader market gains, after U.S. President Trump announced a 90-day pause on so-called reciprocal tariffs. The Stoxx 600 health index surges around 7.2%, outpacing the wider Stoxx 600's 1.2% rise. While pharmaceuticals have so far been spared, Trump reiterated on Tuesday that tariffs on imported medicines remain a possibility. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765489.SGD","03165","LU0109394709.USD","NVS","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","LU2236285917.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0070302665.USD","LU1829250122.USD","BK4585","LU0208291251.USD","LU2417539215.USD","RHHBY","LU0211331839.USD","GSK.UK","LU2456880835.USD","IE00BJT1NW94.SGD","BK4588","LU0320765992.SGD","BK4007","BK4578","BAYRY","BK4568","GSK","IE0002141913.USD","SNY","BK4532","AZN","IE00B2B36J28.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","LU2462157665.USD"],"gpt_icon":0},{"id":"2526846907","title":"PCRX Stock Soars on Exparel Patent Settlement With Generic Players","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846907","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846907?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:29","pubTimestamp":1744126140,"startTime":"0","endTime":"0","summary":"Shares of Pacira BioSciences PCRX are rising today after the company announced that it has entered into a settlement agreement with Fresenius, Jiangsu Hengrui Pharmaceuticals and eVenus Pharmaceuticals Laboratories, related to patents for Exparel .Following the settlement, which resolves the patent litigation brought by Pacira BioSciences against the companies, Consent Judgments will be filed in multiple courts, preventing Fresenius, like the others, from marketing generic bupivacaine liposome injectable suspension before the relevant patents expire, except as outlined in the agreement.Exparel is PCRX’s flagship pain-management product,which was initially launched in 2012. The drug is indicated for postsurgical local analgesia in patients aged six years and older. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.Year to date, shares of Pacira Bi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pcrx-stock-soars-exparel-patent-152900546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","BAYRY","DVAX","BK4139","PCRX","BK4007"],"gpt_icon":0},{"id":"2526846182","title":"RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846182","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846182?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:21","pubTimestamp":1744125660,"startTime":"0","endTime":"0","summary":"Shares of Rhythm Pharmaceuticals RYTM rallied 17.1% on Monday after the company announced that it has met the primary endpoint in a late-stage study of its candidate, setmelanotide, for treating acquired hypothalamic obesity.RYTM’s setmelanotide is an MC4R agonist.Per the data readout, the phase III TRANSCENDstudy met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index  with setmelanotide in adult and pediatric patients compared to placebo. It was observed that all patients with acquired hypothalamic obesity who underwent setmelanotide therapy experienced an average BMI reduction of 16.5% over 52 weeks, whereas those on placebo saw a 3.3% increase.Please note that setmelanotide is already approved as Imcivree in the United States and EU for chronic weight management in adult and pediatric patients aged two years and older with certain genetic conditions. The eligible patient population includes those with monogenic or syndromic o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rytm-stock-rises-17-meeting-152100157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","DVAX","BK4007","BAYRY","RYTM","BK4157","ADMA","BK4139","BK4585","BMI"],"gpt_icon":0},{"id":"2525024795","title":"Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2525024795","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525024795?lang=en_us&edition=fundamental","pubTime":"2025-04-08 01:01","pubTimestamp":1744045260,"startTime":"0","endTime":"0","summary":"1701 GMT - Bayer's filing to review a lower court's decision on a case alleging the company's Roundup product caused cancer is the next step forward in the litigation, Morgan Stanley analysts say. The German pharmaceutical company argues that the \"failure-to-warn\" claims, on which all glyphosate cases are based, are preempted by the Federal Insecticide, Fungicide, and Rodenticide Act's labeling rules, the analyst says. The Supreme Court could potentially decide on whether or not to take the case in the second quarter, with a potential final decision by end 2025 or in the first half of 2026, they say. Shares fall 1.3% to 19.83 euros. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1732800096.USD","LU1162221912.USD","LU1363072403.SGD","LU1668664300.SGD","BK4516","LU1732799900.SGD","LU0106831901.USD","LU0098860793.USD","LU2111349929.HKD","BK4202","BK4581","BK4127","LU1548497426.USD","LU2133065610.SGD","LU1720051108.HKD","LU0912757837.SGD","LU2347655156.SGD","LU0795875086.SGD","BAYRY","LU0320765646.SGD","FORD","LU1989772923.USD","LU0006306889.USD","LU1989772840.SGD","LU0158827948.USD","LU2089284900.SGD","BK4585","LU0267386448.USD","LU1074936037.SGD","LU0795875169.SGD","LU0314104364.USD","LU2023251221.USD","LU0158827781.USD","LU0225283273.USD","BK4504","BK4145","BK4007","LU0106261372.USD","IE00BKVL7J92.USD","LU1720051017.SGD","BK4588","BK4534","LU0971096721.USD","LU2357305700.SGD","LU2271345857.HKD","LU2028103732.USD","LU2089283258.USD"],"gpt_icon":0},{"id":"2525170734","title":"Bayer Asks Supreme Court to Review Roundup Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2525170734","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525170734?lang=en_us&edition=fundamental","pubTime":"2025-04-05 03:14","pubTimestamp":1743794040,"startTime":"0","endTime":"0","summary":"Bayer filed for the Supreme Court to review a lower court's decision on a case alleging the company's Roundup product caused cancer.Bayer said Friday it had filed a petition for a writ of certiorari with the Supreme Court, arguing that a split among federal circuit courts in the Roundup litigation warrants review and resolution by the top court.In 2023, a Missouri Circuit Court returned a verdict in favor of John Durnell, who alleged the weed control product Roundup caused non-Hodgkin's lymphoma. Bayer bought the agrochemical company Monsanto, which makes Roundup, in 2018.The Missouri court's verdict rests on the claim that state law requires companies to warn if their products are carcinogenic, Bayer said.Different courts have reached different conclusions, which is why Bayer is arguing the Supreme Court needs to rule on the issue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2524326247","title":"DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2524326247","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524326247?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:32","pubTimestamp":1743687120,"startTime":"0","endTime":"0","summary":"Shares of Denali Therapeutics DNLI gained 11.8% on Wednesday after the company announced that it has initiated a rolling submission of a biologics license application  for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome . The same has also been received by the Center for Drug Evaluation and Research of the FDA.DNLI reported ongoing collaborative and productive engagement with CDER, aligning with the same on the content of the BLA data package, including the use of CSF HS as a surrogate endpoint for accelerated approval and the path to full approval.Denali expects to complete its BLA submission by mid-May 2025 and is preparing for a potential U.S. commercial launch in late 2025 or early 2026. Tividenofusp alfa, an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase  replacement therapy, enjoys the FDA’s Fast Track and Breakthrough Therapy designations in the United States for MPS II.In the EU, the candidate enjoys the Priority Medicines designation for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dnli-begins-rolling-bla-submission-133200898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DNLI","LU0566484027.USD","BK4532","BK4535","DVAX","BK4548","BK4007","BAYRY","LU1559883803.SGD","BK4139"],"gpt_icon":1},{"id":"2524419264","title":"NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2524419264","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524419264?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:08","pubTimestamp":1743685680,"startTime":"0","endTime":"0","summary":"Nurix TherapeuticsNRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously untreatable transcription factor for autoimmune diseases. This undisclosed target plays a key role in regulating inflammation and is separate from the previously revealed STAT6 degrader program, signed between the companies in 2019. The stock is gaining further in the pre-market hours on Thursday.Nurix and Sanofi first established a strategic collaboration in 2019 to develop and commercialize a portfolio of targeted protein degradation therapies for patients with complex diseases across various therapeutic areas. The partnership utilizes NRIX’s proprietary DEL-AI discovery platform to discover small molecules that promote the degradation of three initially designated drug targets. In 2021, Sanofi exercised its option to expand the number of targets from three to five.The latest update further expands the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrix-stock-sny-licenses-rights-130800564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BAYRY","BK4139","BK4532","LU1559883803.SGD","BK4585","BK4007","BK4588","IE00BFXG1179.USD","SNY","NRIX","LU0566484027.USD"],"gpt_icon":1},{"id":"2524581497","title":"APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2524581497","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524581497?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:11","pubTimestamp":1743599460,"startTime":"0","endTime":"0","summary":"A filing accepted under the regulatory body’s Priority Review pathway reduces the review period to six months from the standard 10 months. This status is awarded to marketing applications for medicines intended to treat serious conditions and that, if approved, would offer a substantial improvement in safety, effectiveness, prevention, or diagnosis of such conditions.A final decision from the FDA is expected on July 28, 2025.Please note that Empaveli is approved in the United States for the treatment of paroxysmal nocturnal hemoglobinuria . The drug is also approved in Europe under the brand name Aspaveli for the same indication.Year to date, shares of Apellis have plunged 28.9% against theindustry’s 2.4% growth.In the VALIANT study, Empaveli was overall well-tolerated with a consistent safety profile. Adverse events were mostly mild to moderate in severity.Novartis recently announced that the FDA has approved Fabhalta for a third indication, C3G, to reduce proteinuria.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apls-empaveli-snda-2-rare-131100793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","CORT","BAYRY","IE00B4R5TH58.HKD","BK4505","BK4139","BK4585","LU0208291251.USD","BK4588","LU1559883803.SGD","LU1093756325.SGD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE0002141913.USD","IE00B2B36J28.USD","LU0320765489.SGD","BK4578","LU0566484027.USD","BK4007","APLS","IE0009355771.USD","LU0070302665.USD","NVS","BK4532"],"gpt_icon":0},{"id":"2524451039","title":"Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2524451039","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524451039?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:27","pubTimestamp":1743586020,"startTime":"0","endTime":"0","summary":"Tesla : The e-vehicle maker's quarterly delivery figures are expected early Wednesday. Shares shed about 1% ahead of the open. The stock has slid this year amid a consumer backlash to Elon Musk's political activities, and tariff uncertainty.Auto stocks: In Germany, shares of automotive supplier Continental  and BMW  both declined. In Asia, Hyundai  lost 1.2%. Ford , General Motors  and Jeep maker Stellantis  were little changed in U.S. premarket trading.Global pharma stocks: Danish Ozempic maker Novo Nordisk  fell more than 2%. Also under pressure: Germany's Bayer , France's Sanofi  and the U.K.'s GSK . Most U.S. drug makers were little changed ahead of the bell.Newsmax : Shares slid more than 30% premarket, continuing a rollercoaster first week of trading for the conservative TV outlet.Grifols : Private-equity firm Brookfield Asset Management  has reopened takeover talks with Grifols. The pharmaceutical company's shares jumped 14% in Madrid midday trading.This item is part of a Wall S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","LU0345769631.USD","BK4561","LU0234570918.USD","LU0648000940.SGD","LU1914381329.SGD","LU0154236417.USD","LU1064927863.SGD","LU1861220033.SGD","BK4532","LU1839511570.USD","BK4612","BAYRY","STLA","GRFS","LU1066051225.USD","LU1066053197.SGD","LU1201861165.SGD","SNY","LU0211331839.USD","CTTAY","SG9999015945.SGD","TSYW.SI","BK4574","BK4533","BK4550","LU0345770308.USD","NVO","GSK","LU0648001328.SGD","BK4007","LU1093756325.SGD","NMAX","F","TSLL","SG9999015978.USD","LU0820562030.AUD","GSK.UK","BK4527","LU0820561909.HKD","BK4598","LU1551013342.USD","LU2756315664.SGD","TSLA","BK4566","LU1720051108.HKD","LU2357305700.SGD","GM","LU2750360641.GBP","LU2108987350.USD"],"gpt_icon":1},{"id":"2524145956","title":"SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2524145956","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524145956?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:44","pubTimestamp":1743515040,"startTime":"0","endTime":"0","summary":"SanofiSNY and partner,Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia  as the first antithrombin-lowering  therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients  with hemophilia A or B with or without factor VIII or IX inhibitors in the United States.Hemophilia A and B are rare, lifelong congenital bleeding disorders that impair the blood's ability to clot, causing excessive bleeding and spontaneous joint bleeds. These can lead to joint damage, chronic pain, which takes a significant toll on the patients’ quality of life.This FDA approval is based on positive data from the phase III ATLAS studies of Qfitlia, which showed clinically significant bleed protection, as measured by annualized bleeding rates , in hemophilia patients with or without inhibitors.Year to date, SNY stock has gained 15% compared with the industry’s 3.4% growth.Further analysis in the open-label extension study, under the ATL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sny-gets-fda-nod-first-134400996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","UBCP","BK4588","SNY","ABR","BK4007","ALNY","BK4211","LU1559883803.SGD","BK4548","BK4585","IE00BFXG1179.USD","CORT","BAYRY","LU0566484027.USD","BK4110","BK4532"],"gpt_icon":0},{"id":"2524917146","title":"AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2524917146","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524917146?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:31","pubTimestamp":1743514260,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN announced that the FDA has approved its blockbuster drug, Imfinzi, for a bladder cancer indication in the United States.Imfinzi is approved in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer , a type of bladder cancer that has spread into the muscle wall of the bladder. The regulatory filing for the drug was reviewed under the FDA’s Priority Review Pathway. This marks the first approval for Imfinzi for a bladder cancer indication.AstraZeneca’s Imfinzi, either as a monotherapy or in combination with chemotherapy, is presently approved for stage III non-small cell lung cancer, extensive-stage small cell lung cancer, locally advanced or metastatic biliary tract cancer and endometrial cancer that is mismatch repair deficient and in combination with Imjudo in unresectable hepatocellular carcinoma in some countries. The drug has also recently been approved for limited-stage small cell lung cancer in the United States and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-gets-fda-nod-133100339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","BK4087","LU0889565916.HKD","LU0109394709.USD","LU2417539215.USD","BK4568","BK4532","CORT","LU2462157665.USD","BK4585","LU2456880835.USD","BK4007","CHMP","LU1829250122.USD","LU1559883803.SGD","LU2236285917.USD","BK4588","BK4139","LU0566484027.USD","DVAX","AZN","BAYRY"],"gpt_icon":0},{"id":"2524977781","title":"FMC, Bayer collaborate to bring Isoflex to European markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2524977781","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524977781?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:36","pubTimestamp":1743453393,"startTime":"0","endTime":"0","summary":"FMC (FMC) announced an agreement with Bayer (BAYRY) to commercialize products containing Isoflex active in the European Union and Great Britain. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fmc-bayer-collaborate-to-bring-isoflex-to-european-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fmc-bayer-collaborate-to-bring-isoflex-to-european-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","FMC","BK4007","LU0471298777.SGD","LU0385154629.USD","BK4585","BK4093","BK4545","BAYRY"],"gpt_icon":0},{"id":"2523075615","title":"Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2523075615","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523075615?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:45","pubTimestamp":1743169500,"startTime":"0","endTime":"0","summary":"Kodiak SciencesKOD reported a loss of 84 cents per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a loss of $1.13 per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company currently does not have any approved products in its portfolio. As a result, it has yet to generate revenues.Research and development expenses were $31.8 million in the reported quarter, down 32% year over year. The decrease was mainly due to reduced manufacturing activities and forfeitures of equity awards, partially offset by clinical activities from active studies.General and administrative expenses were $14.4 million, down 14% year over year, primarily due to lower non-cash stock-based compensation expenses.Kodiak is also enrolling patients in the phase Ib APEX study, which will evaluate its third investigational candidate, KSI-101, in two new cohorts — cohort 1 in patients w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-q4-loss-narrower-expected-134500496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0979878070.USD","DVAX","LU1242518857.USD","BK4605","LU2360106780.USD","IE00BMPRXR70.SGD","LU0823434740.USD","BK4554","BK4512","LU1559883803.SGD","IE00B5949003.HKD","BK4534","BK4505","IE0004445239.USD","LU0082616367.USD","LU0823421333.USD","BK4139","BK4573","BK4529","BK4585","IE0009356076.USD","LU2098885051.SGD","LU0642271901.SGD","LU1951200564.SGD","LU1951198990.SGD","LU2458330243.SGD","CORT","LU2250418816.HKD","LU0823421416.USD","BK4532","BK4141","LU1989764664.SGD","LU0081259029.USD","LU2458330169.SGD","LU1988902786.USD","LU1303367103.USD","LU1064131342.USD","LU1852331112.SGD","KOD","BK4543","LU1880398471.USD","LU0823434583.USD","LU1803068979.SGD","LU1880398554.USD","LU2054465674.USD","LU0127658192.USD","BAYRY","BK4007","BK4588"],"gpt_icon":1},{"id":"2522537272","title":"FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537272","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537272?lang=en_us&edition=fundamental","pubTime":"2025-03-28 03:00","pubTimestamp":1743102000,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx .The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors .Simultaneously, the drug was approved for adult and pediatric patients  with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET .Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.The approval came ahead of the target action date of April 3, 2025.The company is now focused on developing zanzalintinib, a next-generation oral TKI. In January 2025, results from an expansion cohort of the phase Ib/II STELLAR-001 study ev","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-exelixis-cabometyx-label-190000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2242646821.SGD","IE00B2B36J28.USD","LU1868836757.USD","BK4559","LU1989771016.USD","BK4588","IE00BKVL7J92.USD","LU0456855351.SGD","LU0306806265.USD","BK4534","LU1032466523.USD","LU1670710588.SGD","BMY","BK4139","IE0009355771.USD","LU0321505439.SGD","LU0237698245.USD","LU0225284248.USD","CRC","LU0985481810.HKD","LU1868836914.USD","LU1670710661.SGD","IE00BZ1G4Q59.USD","IE0002141913.USD","LU0882574055.USD","LU1718418525.SGD","IE00BSNM7G36.USD","IE00BFXG1179.USD","LU2360032135.SGD","LU1093756168.USD","LU2125154935.USD","EXEL","LU2133065610.SGD","LU1074936037.SGD","LU1261432733.SGD","LU0154236417.USD","LU1585245621.USD","LU0456854461.SGD","RCC","LU0096364046.USD","LU1093756325.SGD","LU0266512127.USD","LU1323610961.USD","LU1868837300.USD","BAYRY","LU0321505868.SGD","IE00BFTCPJ56.SGD","DTC"],"gpt_icon":1},{"id":"2522003463","title":"SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522003463","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522003463?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:46","pubTimestamp":1743079560,"startTime":"0","endTime":"0","summary":"Shares of Soleno TherapeuticsSLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR extended-release tablets for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome . The company expects to launch the drug in the United States in April 2025.Soleno’s Vykat XR, previously referred to as DCCR, is an innovative, once-daily, proprietary extended-release dosage form that contains diazoxide choline, the crystalline salt form of diazoxide. Although not approved for treating PWS, the parent molecule, diazoxide, treats a few rare diseases in neonates, infants, children and adults.Per the PWS Association USA, approximately one in every 15,000 newborns suffers from this rare genetic disorder. The most common symptom of PWS is hyperphagia, an abnormally increased appetite for food, often leading to excessive eating, which takes a serious toll on the quality of life of patients suffering from it. In the long term, hyperp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/slno-stock-rallies-fda-approval-124600150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BAYRY","LU2065171311.SGD","ACAD","LU0566484027.USD","BK4532","CORT","LU2065169927.USD","SLNO","LU2065170008.USD","LU2065171402.SGD","LU1559883803.SGD","PWS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"Post Market","dateTimestamp":1722916800000,"actualEps":null},{"date":"2024-05-14","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"","dateTimestamp":1715659200000,"actualEps":null},{"date":"2024-04-29","symbol":"BAYRY","amount":0.02951,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-04-30","defaultRemindTime":1714397400000,"name":"Bayer A.G.","recordDate":"2024-05-13","payableDate":"2024-04-30","currency":"USD","dateTimestamp":1714363200000,"payDate":"2024-05-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-22","recordDate":"2015-05-27","paymentDate":"2015-06-08","value":1.791948,"currency":"USD"},{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1746244800000}}}